Pulse Biosciences (PLSE) Accounts Payables (2015 - 2025)

Pulse Biosciences' Accounts Payables history runs 11 years deep, the most recent figure standing at $2.8 million for Q4 2025.

• On a quarterly basis, Accounts Payables rose 65.99% year-over-year to $2.8 million in Q4 2025; TTM through Dec 2025 was $2.8 million, a 65.99% increase from a year earlier, with the FY2025 full-year figure at $2.8 million, up 65.99% from the prior year.
• Accounts Payables fell to $2.8 million in Q4 2025 per PLSE's latest filing, from $3.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $3.5 million in Q1 2022 and bottomed at $1.4 million in Q3 2023.
• The 5-year median for Accounts Payables is $2.0 million (2022), against an average of $2.2 million.
• Across the five-year window, Accounts Payables jumped 89.59% in 2021 and tumbled 38.04% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $1.8 million in 2021, then retreated by 14.32% to $1.6 million in 2022, then rose by 16.72% to $1.8 million in 2023, then decreased by 8.88% to $1.7 million in 2024, then jumped by 65.99% to $2.8 million in 2025.
• Per Business Quant, the three latest PLSE Accounts Payables figures stand at $2.8 million (Q4 2025), $3.0 million (Q3 2025), and $2.7 million (Q2 2025).